Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies, including icovamenib and BMF-650, for diabetes and obesity, with research activities focused on the biology of metabolic diseases. Its covalent small molecule drug is a synthetic compound that forms a permanent bond with its target protein. The Company’s clinical candidate, icovamenib, is an investigational oral small molecule that reversibly downmodulates menin, a transcriptional regulator involved in beta-cell biology. Its Phase 2 clinical development includes type 1 and type 2 diabetes, obesity, and combination with GLP-1 receptor agonist therapies. The Company’s second product candidate, BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for the treatment of diabetes and obesity.
Back to dashboard
Company Information
About this company
Key people
Rainer M. Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
Michael J.M. Hitchcock
Interim Chief Executive Officer, Director
Eric Aguiar
Lead Independent Director
Julianne Averill
Independent Director
Elizabeth Faust
Independent Director
Sumita Ray
Independent Director
Click to see more
Key facts
- Shares in issue72.48m
- EPICBMEA
- ISINUS09077A1060
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$126.12m
- Employees37
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.